Matthew Loeb

Matthew Loeb

Auto-generated profile, based on publicly available information

Matthew Loeb

University Oral and Facial Surgery, 651 Helen Keller Boulevard, Tuscaloosa, AL 35404, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2015 in Case Reports in Medicine
Verified
Journal Article
Open access
PDF file
MQMohammed Qaisi
Mohammed Qaisi
MLMatthew Loeb
Matthew Loeb
LMLindsay Montague
Lindsay Montague
RCRon Caloss
Ron Caloss
Brown tumor of hyperparathyroidism (BTHPT) is rare in the United States and not frequently seen in clinical practice. This is likely because early diagnosis and prompt treatment of this disease process prevent the progression and development of BTHPT. Conversely, BTHPT is more common in underdeveloped countries where fewer patients have access to health care and hyperparathyroidism (HPT) goes untreated. It has been reported that the incidence of BTHPT in underdeveloped countries can be as high as 58 to 69 percent in patients with primary HPT. We present a case report of a patient in the United States with a large mandibular BTHPT requiring an extensive resection in the setting of secondary HPT. Despite being rare in this country, it is important for nephrologists, primary care physicians, and oral health care providers to be able to recognize this entity, so that intervention may be rendered early.

28 August 2016 in Case Reports in Dentistry
Verified
Journal Article
Open access
PDF file
MQMohammed Qaisi
Mohammed Qaisi
JHJamie Hargett
Jamie Hargett
MLMatthew Loeb
Matthew Loeb
JBJeffrey Brown
Jeffrey Brown
RCRonald Caloss
Ronald Caloss
Bisphosphonates have been used for years in the treatment of patients with distant bony metastasis and in the prevention of osteoporosis. One of main side effects of these medications is the development of bisphosphonate related osteonecrosis of the jaw (BRONJ) in a small subset of patients. A new class of medications with a shorter half-life, known as receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, was introduced with the hopes of avoiding this side effect. However, reports of osteonecrosis of the jaw after the use of RANKL inhibitors have also been documented. We report on a patient who developed a life threatening osteonecrosis of the jaw with sepsis shortly after switching from a bisphosphonate to a RANKL inhibitor for osteoporosis treatment. This patient developed several soft tissue defects including spontaneous necrosis of the soft palate. To our knowledge this is the first time this presentation has been described.

14 February 2025 in Dental Materials
Verified
Journal Article
Closed access
MSMegha Satpathy
Megha Satpathy
MLMatthew Loeb
Matthew Loeb
RJRose M. Jose
Rose M. Jose
MSMatthew J. Sinclair
Matthew J. Sinclair
YDYuanyuan Duan
Yuanyuan Duan
JGJason Griggs
Jason Griggs